OXOA Stock Overview
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Oxford Biomedica plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.14 |
| 52 Week High | UK£5.40 |
| 52 Week Low | UK£1.79 |
| Beta | 1.03 |
| 1 Month Change | -1.83% |
| 3 Month Change | 9.18% |
| 1 Year Change | -55.79% |
| 3 Year Change | -82.31% |
| 5 Year Change | -72.74% |
| Change since IPO | -95.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| OXOA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.6% | -1.2% | -0.8% |
| 1Y | -55.8% | -15.8% | 1.0% |
Return vs Industry: OXOA underperformed the German Biotechs industry which returned -15.8% over the past year.
Return vs Market: OXOA underperformed the German Market which returned 1% over the past year.
Price Volatility
| OXOA volatility | |
|---|---|
| OXOA Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OXOA has not had significant price volatility in the past 3 months.
Volatility Over Time: OXOA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 891 | Frank Mathias | www.oxb.com |
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product.
Oxford Biomedica plc Fundamentals Summary
| OXOA fundamental statistics | |
|---|---|
| Market cap | €228.36m |
| Earnings (TTM) | -€72.10m |
| Revenue (TTM) | €139.24m |
1.6x
P/S Ratio-3.2x
P/E RatioIs OXOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXOA income statement (TTM) | |
|---|---|
| Revenue | UK£119.02m |
| Cost of Revenue | UK£64.03m |
| Gross Profit | UK£54.99m |
| Other Expenses | UK£116.62m |
| Earnings | -UK£61.63m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 46.20% |
| Net Profit Margin | -51.78% |
| Debt/Equity Ratio | 19.4% |
How did OXOA perform over the long term?
See historical performance and comparison